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See Article, pages 746–754The incidence of Hepatocellular Carcinoma (HCC)
has been rising in both Europe and the United States,
largely due to the growing prevalence of hepatitis C
(HCV) cirrhosis [1]. Despite advances in technology
and available treatments, there has been little improve-
ment in the overall survival likely due to the fact that
most patients are diagnosed at advanced stages [2,3].
Cirrhosis is the most important risk factor for the
development of HCC [4]. HCV and hepatitis B
(HBV) are the major etiological agents that lead to
HCC [5,6], though all etiologies that lead to cirrhosis
also increase the risk of developing HCC. The rationale
for surveillance is the use of a relatively simple and
inexpensive test in a large number of individuals at risk
for cancer with the goals of reducing morbidity and
mortality [7]. Because patients with cirrhosis are at a
high risk for developing HCC, guidelines recommend
surveillance of these patients [8].
An algorithm for the diagnosis of HCC has been
established for surveillance tests that result abnormal
[8]. These guidelines indicate that nodules developed in
cirrhotic patients >2 cm in diameter with typical ﬁnd-
ings for HCC (enhancement in arterial phase followed
by washout in portal venous phase) on cross-sectional
imaging or contrast-enhanced ultrasound do not require
biopsy conﬁrmation. If lesions reveal atypical features
on imaging, then biopsy is required to establish the diag-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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between 1 and 2 cm in diameter, the guidelines are more
stringent and required two imaging tests (cross-sectional
imaging, contrast-enhanced ultrasound and/or arterio-
gram) for the diagnosis of HCC if they have typical fea-
tures (enhancement in arterial phase followed by
washout in portal venous phase). Otherwise, a biopsy
of the lesion is required for the diagnostic conﬁrmation
of HCC. A recent study showed that 84% of nodules
>2 cm in diameter met the typical criteria of HCC and
did not require biopsy conﬁrmation, but only 44% of
the nodules between 1 and 2 cm met this criteria [9]. A
study that validated the AASLD guidelines showed that
the sensitivity of these non-invasive criteria was 33% and
biopsy was required for the diagnosis of HCC of nod-
ules in patients with cirrhosis [10]. The goal of surveil-
lance in patients with cirrhosis would be the detection
of early HCC (single lesion between 2 and 5 cm or <3
lesions each <3 cm) or very early HCC (single lesion
<2 cm) in which curative therapy with either radiofre-
quency ablation or surgical resection can be applied
[8]. Very early HCC can be determined by size (<2 cm)
but also by the presence of tumor cell invasion into
the intratumoral portal tracts (stromal invasion) in the
pathological examination [11]. Therefore, for the diag-
nosis of HCC in nodules <2 cm in patients with cirrho-
sis, liver biopsy will be a critical part of the diagnostic
armamentarium.
There are concerns with performing biopsy in
patients with cirrhosis. One is bleeding. The rate of
bleeding has been established to be 0–1.4% [12]. There-
fore the use of biopsy for the diagnosis of HCC should
be restricted to patients with cirrhosis in a surveillancePublished by Elsevier B.V. All rights reserved.
660 J.A. Marrero / Journal of Hepatology 50 (2009) 659–661program with compensated liver disease and an accept-
able risk of bleeding. The second concern is the potential
for seeding along the needle track. We have shown that
using a coaxial cutting needle technique with a 17-gauge
introducer and 18-gauge biopsy needle reduces seeding
signiﬁcantly [13], and it is considered safe from this
aspect. The third most important concern with biopsy
is the lack of agreement even among expert pathologists
regarding the histological diagnosis of HCC [14]. There
are now international guidelines with consensus as to
pathological criteria for the diagnosis of HCC and more
importantly the diﬀerence between high-grade dysplastic
nodules and very well-diﬀerentiated HCC. Hence histo-
logical evaluation, using liver biopsy, of nodules seen
during surveillance of cirrhotic patients is necessary
and will most likely be employed more widely for this
purpose in the future.
In a short time genomic studies have rapidly evolved
from the theory to elegant translational studies that
have the potential to impact clinical medicine. The
genomic proﬁle of HCC has been identiﬁed [15,16].
One of the most important studies that translated geno-
mic studies into clinical practice evaluated 55 genes to
determine a signature for the diagnosis of early HCC
[17]. The authors found that a 3-gene set had a discrim-
inative accuracy of 94%, but, however, glypican-3
(GPC3) provided most of the predictive power in this
set. Another study analyzed 12,600 genes of which a
set of 95 genes provided a molecular signature that dis-
tinguished between early HCC components and their
noncancerous liver tissues, and a set of 92 genes distin-
guished between progressed and early HCC compo-
nents [18]. Of these genes, the most abundantly up-
regulated genes in early HCC components (P < 0.001)
was heat-shock protein 70 (HSP70). In another proﬁl-
ing study in HCC, the authors identiﬁed several clones
speciﬁcally expressed during malignant cell prolifera-
tion by screening a complementary DNA library con-
structed from a human primary liver cancer [19]. One
clone was identiﬁed as the glutamine synthetase (GS)
transcript, its expression is tightly regulated during
development, especially in the hepatic lobule. A recent
study evaluated 52 surgically removed non-malignant
nodules (15 LRNs, 15 LGDNs, 22 HGDNs) and 53
HCCs (10 early, 22 grade 1, and 21 grade 2-3) or
HSP70, GPC3, and GS [20]. The 3-marker panel, when
at least 2 of them were positive, the sensitivity and spec-
iﬁcity for the detection of eHCC-G1 were respectively
72% and 100%; the most sensitive combination was
HSP70+/GPC3+ (59%) when a 2-marker panel was
used. This was the ﬁrst conﬁrmation that these 3 genes
may lead to the pathological diﬀerentiation between dys-
plasia and early HCC. The main drawback of this pilot
study was that it required surgical specimens.
In this issue of the Journal, Di Tommaso and col-
leagues evaluated the panel consisting of HSP70,GPC3 and GS in liver biopsy specimens for the distinc-
tion between high-grade dysplasia and well-diﬀerenti-
ated HCC in liver biopsy specimens, [21]. This is a
retrospective study from the pathology ﬁles in 2 Italian
centers and one Korean center. The specimens were col-
lected with 18- to 19-gauge needles. There were large
regenerative nodules (n = 13), low-grade dysplastic nod-
ules (n = 21), high-grade dysplastic nodules (HGDN)
(n = 50), very-well diﬀerentiated HCC (VWD) (n = 17),
well-diﬀerentiated HCC (WD) (n = 40) and moder-
ately–poorly diﬀerentiated HCC (MPD) (n = 35). The
pathological diagnosis was based on internationally-rec-
ognized criteria. The expression was determined by
immunohistochemistry with positive GPC3 and HSP70
showing more than 5% of hepatocytes immunoreactive.
GS staining of lesional areas of strong and diﬀuse immu-
noreactivity was considered positive. When at least 2
markers were positive the sensitivity, speciﬁcity, positive
predictive value and accuracy was 58.7%, 100%, 100%,
78.4%, respectively, for diﬀerentiating HCC from non-
malignant nodules. When using at least one marker
showing immunoreactivity, the sensitivity increased to
93.5% but the speciﬁcity decreased to 85.7%. However,
the most important part of the study was evaluating
the performance of the markers for diﬀerentiating
HGDN and VWD HCC. When at least 2 markers were
positive the sensitivity, speciﬁcity, positive predictive
value and accuracy was 49.1%, 100%, 100%, 72.9%,
respectively. Overall GPC3 had the best performance
for diﬀerentiating HGDN from VWDHCC with a sensi-
tivity of 61.4%, speciﬁcity of 92%, and accuracy of
75.7%. The authors conclude that 2 out 3 immunoreac-
tivity are useful to detect VWDHCC, with GPC3 having
the best performance of all the markers studied.
There are some important points that need to be taken
into account. One, the patients with HCC included in
this study had tumor sizes ranging between 2 and 5 cm
in diameter and did not include patients with very early
HCC. Dynamic cross-sectional imaging or contrast-
enhanced ultrasound can lead to the diagnosis of HCC
in the majority of these patients without the need for liver
biopsy. Further study in those with very early HCC
needs to be performed. Second, specimen size is of
utmost importance for a successful interpretation of a
liver biopsy [21] as well as for performing immunohisto-
chemistry and other molecular studies. Di Tommaso and
colleagues do not indicate the size of the samples in their
study and at which specimen size immunohistochemistry
tests yields accurate estimates of cancer risk. Lastly, as
with other immunohistochemistry studies, an objective
measure of positive staining may lead to more accurate
results rather than relying on subjective criteria [22],
and perhaps more sensitive antibodies may improve the
performance as well.
However, this important study validates in liver
biopsy specimens, critical for the diagnosis of very early
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markers selected as part of independent studies evaluat-
ing the genomic signature of patients with early HCC. As
the genomic signature of VWD HCC is further clariﬁed,
it is likely that a more sensitive and speciﬁc panel will be
developed. The next step is to prospectively evaluate the
AASLD criteria for diagnosing very early HCC (1–2 cm
in diameter on imaging) in patients with cirrhosis and to
determine whether this panel (or a reﬁned one) can
improve the diagnostic accuracy. These are exciting
times in ﬁeld of HCC, in which genomics and proteo-
mics are increasingly studied in the development of clin-
ical tools for surveillance, diagnosis, prognosis and for
measuring response to treatment.References
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